Evidence map›Paper›PMID 34831095›Full record

ArticleCells2021

Hypoxic Incubation Conditions for Optimized Manufacture of Tenocyte-Based Active Pharmaceutical Ingredients of Homologous Standardized Transplant Products in Tendon Regenerative Medicine.

Annick Jeannerat, Cédric Peneveyre, Florence Armand, Diego Chiappe, Romain Hamelin, Corinne Scaletta, Nathalie Hirt-Burri, Anthony de Buys Roessingh, Wassim Raffoul, Lee Ann Applegate and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Annick JeanneratApplied Research Department, LAM Biotechnologies SA, CH-1066 Épalinges, Switzerland.
Cédric PeneveyreApplied Research Department, LAM Biotechnologies SA, CH-1066 Épalinges, Switzerland.
Florence ArmandProteomics Core Facility and Technology Platform, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
Diego ChiappeProteomics Core Facility and Technology Platform, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
Romain HamelinProteomics Core Facility and Technology Platform, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
Corinne ScalettaRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, Switzerland.
Nathalie Hirt-BurriRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, Switzerland.
Anthony de Buys RoessinghChildren and Adolescent Surgery Service, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0002-2174-4549
Wassim RaffoulLausanne Burn Center, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0002-3524-0077
Lee Ann ApplegateRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Épalinges, Switzerland.ORCID 0000-0002-7346-9921
Alexis LaurentApplied Research Department, LAM Biotechnologies SA, CH-1066 Épalinges, Switzerland.
University of Lausanne · CHÉcole Polytechnique Fédérale de Lausanne · CHUniversity of Zurich · CH

Funding

Service of Promotion of the Economy and Inno- 875 vation of the Canton of Vaud (SPEI) LADE 20-411Service of Promotion of the Economy and Inno- 875 vation of the Canton of Vaud (SPEI) LADE 20-472
6 · The paper itself

Abstract

Human fetal progenitor tenocytes (hFPT) produced in defined cell bank systems have recently been characterized and qualified as potential therapeutic cell sources in tendon regenerative medicine. In view of further developing the manufacture processes of such cell-based active pharmaceutical ingredients (API), the effects of hypoxic in vitro culture expansion on key cellular characteristics or process parameters were evaluated. To this end, multiple aspects were comparatively assessed in normoxic incubation (i.e., 5% CO

Indexed as

Regenerative MedicineAdipogenesisBiomarkersCell HypoxiaCell ProliferationCells, CulturedCell ShapeCell SizeDown-RegulationExtracellular Matrix ProteinsFetusGene OntologyHumansHypoxia-Inducible Factor 1, alpha SubunitModels, BiologicalOsteogenesisBiomarkersExtracellular Matrix ProteinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitPharmaceutical Preparationsactive pharmaceutical ingredientscell bankingcell manufacturehuman progenitor tenocyteshypoxiaoptimizationproteomicsregenerative medicinestandardized transplantstendon affections

Identifiers

PMID34831095
PMCPMC8616528
OpenAlexW3209486917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.